1. Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barre syndrome. J Infect Dis 2008;198(2):226-33.

2. Safranek TJ, Lawrence DN, Kurland LT, Culver DH, Wiederholt WC, Hayner NS, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133(9):940-51.

3. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barre syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981;304(26):1557-61.

4. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillain-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339(25):1797-802.

5. van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM, et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119(10):1036-41.

6. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, et al. Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38(4-5):339-44.

7. Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R, et al. Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med 2003;25(3):254-7.

8. Filippi A, Vanuzzo D, Bignamini AA, Mazzaglia G, Cricelli C, Catapano AL. The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J 2005;6(4):311-4.

9. Trifiro G, Spina E, Brignoli O, Sessa E, Caputi AP, Mazzaglia G. Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999-2002. Eur J Clin Pharmacol 2005;61(1):47-53.

10. Malig C. The Civil Registration System in Denmark. IIVRS Technical Paper. Bethesda, Maryland: International Institute for Vital Registration and Statistics, 1996.

11. Andersen TF, Madsen M, Jorgensen J, Mellemkjoer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999;46(3):263-8.

12. Bonhoeffer J, Menkes J, Gold MS, de Souza-Brito G, Fisher MC, Halsey N, et al. Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004;22(5-6):557-62.

13. Ruggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5675-84.

14. Sejvar JJ, Kohl KS, Bilynsky R, Blumberg D, Cvetkovich T, Galama J, et al. Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5771-92.

15. Khasnis A, Langford CA. Update on vasculitis. J Allergy Clin Immunol 2009;123(6):1226-36.

16. Miller A, Basu N, Luqmani R. Assessment of systemic vasculitis. Autoimmun Rev 2008;8(2):170-5.

17. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre syndrome: an update. J Clin Neurosci 2009;16(6):733-41.

18. Tiemstra JD, Khatkhate N. Bell's palsy: diagnosis and management. Am Fam Physician 2007;76(7):997-1002.

19. Ahmed A. When is facial paralysis Bell palsy? Current diagnosis and treatment. Cleve Clin J Med 2005;72(5):398-401, 405.

20. Skowronski DM, Strauss B, De Serres G, MacDonald D, Marion SA, Naus M, et al. Oculo-respiratory syndrome: a new influenza vaccine-associated adverse event? Clin Infect Dis 2003;36(6):705-13.

21. Wise RP, Bonhoeffer J, Beeler J, Donato H, Downie P, Matthews D, et al. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25(31):5717-24.

22. Boberg KM. Prevalence and epidemiology of autoimmune hepatitis. Clin Liver Dis 2002; 6(3):635-647.

23. Primo J, Merino C, Fernandez J, Moles JR, Llorca P, Hinojosa J. [Incidence and prevalence of autoimmune hepatitis in the area of the Hospital de Sagunto (Spain)]. Gastroenterol Hepatol 2004; 27(4):239-243.

24. Werner M+, Prytz H, Ohlsson B, Almer S, Bj+Ârnsson E, Bergquist A et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: A nationwide study. Scandinavian Journal of Gastroenterology 2008; 43(10):1232-1240.

25. Matsui E. A Population-Based Study of the Incidence, Cause, and Severity of Anaphylaxis in the United Kingdom. Pediatrics 2005; 116(2):549-54a.

26. Sheikh A, Hippisley-Cox J, Newton J, Fenty J. Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England. J R Soc Med 2008; 101(3):139-143.

27. Sheikh A, Alves B. Age, sex, geographical and socio-economic variations in admissions for anaphylaxis: analysis of four years of English hospital data. Clinical and Experimental Allergy 2001; 31(10):1571-1576.

28. Rowlands S, Hooper R, Hughes R, Burney P. The epidemiology and treatment of Bell's palsy in the UK. European Journal of Neurology 2002; 9(1):63-67.

29. Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry 1997; 62(4):310-318.

30. Kotsopoulos IA, van MT, Kessels FG, de Krom MC, Knottnerus JA. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002; 43(11):1402-1409.

31. Jmor F, Emsley H, Fischer M, Solomon T, Lewthwaite P. The incidence of acute encephalitis syndrome in Western industrialised and tropical countries. Virology Journal 2008; 5(1):134.

32. McGrogan A, Madle GC, Seaman HE, de Vries CS. The Epidemiology of Guillain-Barre Syndrome Worldwide A Systematic Literature Review. Neuroepidemiology 2009; 32(2):150-163.

33. Rees JH, Thompson RD, Smeeton NC, Hughes RA. Epidemiological study of Guillain-Barre syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64(1):74-77.

34. Soderstrom M. The clinical and paraclinical profile of optic neuritis: a prospective study. Ital J Neurol Sci 1995; 16(3):167-176.

35. Kinnunen E. The incidence of optic neuritis and its prognosis for multiple sclerosis. Acta Neurol Scand 1983; 68(6):371-377.

36. Congia S, Vacca MA, Tronci S. Epidemiologic and clinical features of optic neuritis in the 20th and 21st sanitary districts of the Sardinia (Italy). Acta Neurol (Napoli) 1989; 11(1):10-14.

37. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995; 45(2):244-250.

38. Optic Neuritis Study Group. The Clinical Profile of Optic Neuritis: Experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1991; 109(12):1673-1678.

39. Beghi E, Kurland LT, Mulder DW. Incidence of Acute Transverse Myelitis in Rochester, Minnesota, 1970-1980, and Implications with Respect to Influenza Vaccine. Neuroepidemiology 1982; 1:176-188.

40. Jeffery DR, Mandler RN, Davis LE. Transverse Myelitis: Retrospective Analysis of 33 Cases, With Differentiation of Cases Associated With Multiple Sclerosis and Parainfectious Events. Arch Neurol 1993; 50(5):532-535.

41. Berman M, Feldman S, Alter M, Zilber N, Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology 1981; 31(8):966-971.

42. Young J, Quinn S, Hurrell M, Taylor B. Clinically isolated acute transverse myelitis: prognostic features and incidence. Multiple Sclerosis 2009; 15(11):1295-1302.